ALVOTECH
“ We have a strong supplier network and are ready and excited to transition to the commercial phase .”
GERHARD HELMERICH HEAD OF GLOBAL SUPPLY CHAIN , ALVOTECH
in the end . We got through it because our people worked together to find the best way of collaborating with suppliers .”
Among its suppliers are Thermo Fisher , Purolite and Asahi Kasei Bioprocess .
“ They have been supporting us since the start of our journey and are key suppliers to Alvotech ,” says Helmerich . “ Thermo Fisher supplies a variety of different materials and equipment , Purolite is one of our resin suppliers and Asahi Kasei delivers different kinds of filters .”
“ We are very thankful to have them on board , supporting our mission . All our partners go the extra mile to address the needs we have . They think out of the box , are very proactive and focused on continuous improvement .” As well as supportive suppliers , Helmerich says he has an outstanding supply chain team , “ eager to solve problems and meet challenges ”.
“ I can say we are grateful for the pandemic experience because it ’ s allowed us to strengthen our relationships with many key partners , who of course have also been facing their own challenges . Extraordinary commitment and support from both sides is what made the difference .”
Although Alvotech has biosimilar candidates under development and regulatory review , so far it has none on the market . So , is its supply chain ready to swing into action when needed ?
“ Absolutely ,” says Helmerich . “ Throughout 2021 we finalised the blueprint for our supply chain organisation . We have a strong supplier network and are ready and excited to transition to the commercial phase .”
The company ’ s product pipeline contains several biosimilars aimed at treating a mix of autoimmune , oncology and inflammatory conditions . The most advanced asset in its pipeline is AVT02 - a proposed biosimilar for high-concentration adalimumab .
Adalimumab is an anti-TNF drug that is sold under the brand name Humira ®. In November 2021 , AVT02 was approved by the European Medicines Agency .
The company ’ s other disclosed biosimilar candidates include additional targets in immunology , ophthalmology , oncology and bone disease , specifically Stelara ® ( ustekinumab ) and Simponi ®/ Simponi
healthcareglobal . com 45